MEDIA RELEASE

QT VASCULAR EXPANDS ITS CONVERTIBLE BONDS BY US$6.06 MILLION

Highlights:

- **New bonds subscriptions are undertaken by a substantial shareholder, Luminor Pacific, and a group of investors, who are investing US$1.86 million and US$4.20 million respectively**
- **Funding will advance the Group's strategic partnership discussions and enhance resources allocation toward the development of the Group's unique products in the form of Drug-Coated Chocolate®**

SINGAPORE, 27 January 2016 – QT Vascular Ltd., together with its subsidiaries ("**QT Vascular**" or the "**Group**"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, has entered into two bonds subscription agreements with various investors totalling US$6.06 million. This funding will, *inter alia*, strengthen the Group's resources to enable it to advance its strategic plans including partnership opportunities.

QT Vascular has also entered into a US$4.20 million convertible bonds subscription agreement with 10 individual investors, which is convertible into 45,281,250 QT Vascular shares. QT Vascular's wholly-owned subsidiary, Quattro Vascular Pte. Ltd. ("**Quattro Vascular**") has entered into a US$1.86 million exchangeable bonds subscription agreement with Luminor Pacific Fund 2 Ltd ("**Luminor Pacific**") (the "**Exchangeable Bond**") at the same time. This investment is exchangeable into 20,053,125 QT Vascular shares. The obligation for Luminor Pacific to subscribe and pay for the Exchangeable Bond is subject to, amongst others, approval by the shareholders of QT Vascular at an extraordinary general meeting to be convened by QT Vascular.

Dr Foo Fatt Kah, Managing Director and co-founder of Luminor Capital Pte Ltd, the investment manager for Luminor Pacific, said, ***"We are truly encouraged by the real-life human outcomes of Chocolate®. It is proving to be a ground-breaking medical device as seen by the outstanding clinical data thus far, and the future prospects of drug-coated Chocolate® particularly excites us. Our continued investment in QT Vascular reiterates our***

commitment and underscores our confidence to QT Vascular's highly capable management team."

Dr. Eitan Konstantino, Ph.D., Chief Executive Officer of QT Vascular said, ***"We are encouraged by the confidence that the investors have in our products and our prospects. This funding will allow us to advance our strategic partnership discussions while enhancing our resources allocation towards the development of our unique Drug-Coated Chocolate®."***

The bonds will have a 12-month maturity period from the closing date of the respective bonds. The bonds can be exchanged or converted into ordinary QT Vascular shares at the fixed price of S$0.128 per share. This represents a 35.88% premium over QT Vascular's weighted average price of S$0.0942 for trades done on 27 January 2016. The bonds can be exchanged or converted at any time at the sole discretion of the investors prior to their respective maturity dates.

The funding support will provide additional funding needs for the Group's operations and allow QT Vascular to continue with the development of its unique drug-coated Chocolate® platform, as it works towards obtaining the necessary regulatory approvals, particularly the United States Food and Drug Administration approval. With the necessary approvals in place, the Group will be able to realise the strong potential of its drug-coated Chocolate® platform.

~~ End ~~

This media release is to be read in conjunction with the Company's announcement posted on the SGX website on 27 January 2016.

ABOUT QT VASCULAR LTD. (SGX Stock code: 5I0)

QT Vascular Ltd. together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC ("**TriReme Medical**"), based in Pleasanton, California. TriReme Medical's range of percutaneous transluminal angioplasty ("**PTA"**) and percutaneous transluminal coronary angioplasty ("**PTCA**") products include (i) Chocolate® PTA Balloon Catheter, (ii) Chocolate® PTCA Balloon Catheter, (iii) GliderXtreme™ PTA Balloon Catheter, (iv) GliderfleX® PTA Balloon Catheter and (v) Glider™ PTCA Balloon Catheter, all of which have the CE Mark that allows them to be sold in Europe, and FDA clearance to be sold in the United States. Additionally, the GliderXtreme™ PTA Balloon

Catheter has the regulatory clearance in China and Japan, while the Glider™ PTCA Balloon Catheter has the regulatory clearance in Japan. These products are sold through its main distributors: (i) Cordis Corporation (a wholly-owned subsidiary of Cardinal Health, Inc.), (ii) Shandong Weigao Group Medical Polymer Co Ltd and (iii) Century Medical, Inc.

For more information, please visit the company website at www.qtvascular.com

Issued on behalf of **QT VASCULAR LTD.** by:

WATERBROOKS CONSULTANTS PTE LTD
Tel: +65 6100 2228

For media and analysts, please contact:

Mr Wayne Koo	(M): +65 9338 8166	wayne.koo@waterbrooks.com.sg
Ms Lynette Tan	(M): +65 9687 2023	lynette@waterbrooks.com.sg
Ms Angeline Cheong	(M): +65 9666 0977	angeline@waterbrooks.com.sg

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

QT Vascular Ltd. (the "Company") was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone +65 6229 8088.